


FINAL REPORT

ASSESSMENT OF DERMAL TOLERABILITY OF A COSMETIC PRODUCT

<u>Study n°</u>	CF024/14-04
<u>Study Protocol code</u>	REL/0703/2014/CLI/SAB
<u>Sponsor</u>	Chase Life Extension Foundation Ltd, 64 Stapleford Crescent, Browns Bay North SHore, Auckland 0630 New Zealand
<u>Analyzed substance</u>	TAM- 818 Serum Batch:F7NCT/ 200114

The results reported herein do exclusively refer to the tested sample

This report may not be reproduced, neither entirely nor in part except with an explicitly written authorization from the Study Center



Study Director:

Dr. Samuele Burastero –Medical Doctor, Board Certified Specialist in Allergology and Clinical immunology,
Researcher at the Scientific Institute

Date: 15/05/2014

Address: Istituto Scientifico Ospedale san Raffaele
Via Olgettina, 58
20132 – Milano (MI)
Italy

Quality Assurance:

Dr.ssa Valentina Zanoletti –Chemistry and Pharmaceutical Technology

Date: 15/05/2014

Address: Abich S.r.l.-Clinical and Cosmetological Trials Center
Via Bruno Buozzi, 4
20090 - Vimodrone (MI) - Italy


Assay Center Director

Dr. Stefano Todeschi –Biologist and Specialist in Clinical Pathology

Date: 15/05/2014

Adress: Abich S.r.l.-Clinical and Cosmetological Trials Center
Via Bruno Buozzi, 4
20090 - Vimodrone (MI) - Italy

Other professional figures involved in the study:



AUTHENTICITY OF RESULTS

I hereby declare that the study concerned by this report was carried out under my responsibility, according to the experimental protocol and the quality plan of the Abich S.r.l.. I also state that, whenever applicable, all procedures were compliant with the principles of Good Clinical Practice.


All relevant observations and data recorded during the test are reported in this study report.

I certify the re-reading of this report and do agree with its content.

The Medical Director
Dott. Samuele Burastero

Date:

15/05/2014



ABICH S.r.l.

Biological and Chemical Analysis
Toxicology, Research and Services


Report No: REL/0703/2014/CLI/SAB

Version: English

Page: 4 of 23

INDEX

SUMMARY	5
1. AIM OF THE STUDY	6
2. TEST SUBSTANCE	6
3. REGULATORY ASPECTS	6
4. PANEL RECRUITMENT	6
5. ESSAY METHODOLOGY	10
5.1. Structure of the study	10
5.2. Study duration	10
5.3. Environmental conditions	10
5.4. Method of application	10
5.5. Evaluated skin areas	10
6. ASSESSMENT OF DERMAL TOLERABILITY	10
6.1. Clinical Evaluation	10
6.2. Subjective Evaluation	10
7. DATA ANALYSIS AND PRODUCT CLASSIFICATION	11
8. RESULTS	11
8.1. Results of the clinical evaluation	11
8.2. Results of subjective evaluation	12
9. DISCUSSION AND CONCLUSIONS	12
10. ARCHIVING	12
11. REFERENCES	13
12. ANNEXES	14



SUMMARY

On behalf of the Company **Chase Life Extension Foundation Ltd** on the test substance **TAM- 818 Serum** a study was conducted in order to evaluate its tolerability with human skin (irritant potential) of 100 healthy volunteers under normal use conditions.

To this purpose all volunteers have used the product at home twice a day for a period of 30 days.

The entire study was carried out under medical supervision.

The basal conditions and the integrity of the examined skin area (face) were evaluated and registered before the beginning of the study to evaluate the suitability of the 100 subjects participating to the study ; the same evaluations were repeated after 15 and 30 days of bi-daily products usage.

The first utilization of the product on the face was carried out in the laboratory under the supervision of the Abich specialized personnel to immediately assess potential reactions of intolerance to the product.

During the Clinical assessment, the skin reactions were evaluated according to these defined parameters:

- erythema,
- desquamation,
- oedema,
- vesicles,

and scored with gravity values ranging from 0 to 3.

This allowed to extrapolate the Average Irritation Index at each experimental time.

Any other undesirable local reactions and subjective effects were also observed and registered.

In addition at the end of the study was asked the volunteers to express a subjective judgment about the degree of tolerance of the product.


The calculation of Mean Irritation Index (MII), under the adopted experimental conditions, allowed to classify the test substance

TAM- 818 Serum

as **NOT IRRITANT and TOLERATE/COMPATIBLE with the skin**

The study was performed at the Abich S.r.l. Clinical and Cosmetological Trials Center at Via Bruno Buozzi, 4 – 20090 – Vimodrone (Milan)-Italy under the direction of Dr. Samuel Burastero, MD, Board Certified Specialist in Allergology and Clinical Immunology, San Raffaele Scientific Institute Milan.

The experimentation started the 27th February, 2014 and ended the 12nd May, 2014.



DISCLAIMER

According to COLIPA guidelines, the test was performed with the assumption that the Sponsor under its responsibility provided to the personnel of the Abich Clinical and Cosmetological Trials Center, truthful information on any ingredient of the test product endowed with potential toxicological relevance. On the basis of such information, a general assessment of the toxicological information concerning the product was preliminarily carried out and ethical implications as to its use during the present study have been considered.

EXPERIMENTAL PROCEDURE

1. AIM OF THE STUDY

This study is finalized to evaluate the compatibility of the test product with the healthy skin of 100 subject through an intensive and extended use of the product.

2. TEST SUBSTANCE

The test substance consists of an emulsion of a light yellow colour for cosmetic use.

<u>Name:</u>	TA Serum 818
<u>Batch/ Formule code:</u>	F7NCT/200114
<u>Sample Code Abich:</u>	0824/14-07
<u>INCI composition:</u>	see annex
<u>Pao / Expiration date:</u>	n.a.
<u>Storage conditions:</u>	room temperature

The characterization of the test substance is under responsibility of the Sponsor.


3. REGULATORY ASPECTS

This study has been carried out in compliance with the most recent recommendations of the Helsinki Declaration (Helsinki Declaration 64th WMA General Assembly, Fortaleza, Brazil, October 2013) and has followed the "Guidelines for the Assessment of Skin Tolerance of Potentially irritant Cosmetic ingredients", COLIPA, 1997.

4. PANEL RECRUITMENT

A) CHARACTERISTICS OF THE PANEL

The study was performed on 100 healthy female volunteers, aged from 36 to 65, who were identified from the database of volunteers of the Abich Clinical and Cosmetological Trials Center, and who were evaluated as appropriate for participation in the study and not suffering from diseases to the skin areas to treat. Before the beginning of the study each volunteer has read and signed an informative form (informed



consent form, C.I.). Each volunteers has had the opportunity to ask any kind of questions regarding the study to which was given an exhaustive answer. The volunteer was explained the aim of the test, the procedure and the possible risks related.


Only after signature of the informed consent the participation in the study was permitted.

Only volunteers in good general health conditions were included in the study.


The originals of these informed consent forms were archived at the Abich Cosmetic Lab. All subjects signed a consent allowing to treat personal data according to the Italian law (privacy. D.Lgs 196/2003).

Table 1: Volunteers participant to the study.

N° Vol.	Vol. Code	Age
1	adci526	41
2	ancon12	48
3	aniz367	50
4	anla484	39
5	anla7	47
6	anpan13	48
7	anpe409	52
8	anpe440	60
9	ansa120	60
10	arsu460	54
11	bami523	61
12	brti103	57
13	cabo441	54
14	caca55	58
15	cama505	41
16	caro420	37
17	chce155	48
18	clbe483	39
19	criquat14	56
20	crt129	39
21	dabe206	47
22	dalo334	47
23	debo349	58
24	dima287	48
25	dipi365	59
26	doca447	53
27	dogi445	45
28	elca122	40
29	eliv342	55
30	eman525	50
31	esa8	47
32	fead421	58



33	fipl275	62
34	fipa355	40
35	frga90	51
36	frma177	60
37	gaam497	53
38	gabr259	48
39	Gati439	47
40	gica434	39
41	giga455	51
42	gigr222	49
43	gima500	58
44	gipi527	59
45	giufi20	53
46	kadi493	38
47	lalom4	64
48	lata251	49
49	lili254	59
50	liva137	49
51	lode61	46
52	loma2	51
53	lopo479	63
54	lotu144	57
55	lua476	54
56	lubel22	56
57	lude228	45
58	ludi5	47
59	lufiu18	59
60	luge86	55
61	lupr276	45
62	luri265	46
63	lute520	60
64	lutuc9	60
65	maal258	54
66	maap492	45
67	maca268	55
68	maca64	45
69	macat1	61
70	made135	59
71	malu257	48
72	mama444	46



73	mela164	42
74	migi167	43
75	miro432	52
76	mobe354	53
77	more267	50
78	nagr443	51
79	nama501	50
80	paba487	36
81	pamu418	51
82	pavi307	59
83	pivi463	65
84	rast348	54
85	ricl480	57
86	riia62	65
87	roca128	47
88	roia359	58
89	romi370	65
90	rote181	62
91	rova262	51
92	saca272	45
93	saca38	36
94	sagi270	45
95	sapo213	55
96	sigi469	48
97	tecri3	41
98	tiba281	52
99	tira309	48
100	vidi524	55
MEAN		52


B) EXCLUSION CRITERIA

The following criteria of exclusion were applied:

- Pregnancy or nursing condition.
- Medication (local and/or systemic) which might interfere with the test evaluation.
- Subjects with signs of irritation at the application site.
- Subjects with dermatological problems which that might interfere with the study.
- Simultaneous participation to other studies, which that might interfere with the test evaluation.

Moreover, after study start, the following withdrawal criteria were applied:

- Volunteers who did not follow the conditions as described in the informed consent form, C.I.;
- Volunteers who suffered any illness or accident or developed any condition which could affect the outcome of the study;
- Volunteers who did not longer wish to participate in the study.



C) CRITERIA FOR STUDY WITHDRAWAL

After study start, the following withdrawal criteria were applied:

- volunteers who did not longer wish to participate in the study;
- volunteers who during the study suffered any illness or accident or developed any condition which could affect the outcome of the study;
- volunteers who did not follow the conditions as described in the Study Protocol.

5. ESSAY METHODOLOGY

5.1. Structure of the study

The study was performed with an open observational design.

5.2. Study duration

The study lasted 30 days for each volunteer.

5.3. Environmental conditions

The study was performed in standard environmental conditions for each observing / reading time specified, maintaining temperature and humidity constant.

5.4. Method of application

The product under examination was used by each volunteer at home twice a day for a period of 30 days; the product was applied on the entire face massaging until absorption.

5.5. Evaluated skin areas

The clinical evaluation was carried out on the treated skin area of the face.

6. ASSESSMENT OF DERMAL TOLERABILITY

6.1. Clinical Evaluation

The basal conditions of the analyzed skin area were evaluated and registered before the beginning of the study; the same evaluations were repeated after 15 days (T15) and 30 days (T30) of bi-daily product application in order to evaluate any possible skin reaction.

In particular, the following parameters were considered: erythema, desquamation, oedema and vesicles. Each parameter was scored with values ranging from 0 to 3 to express differences in severity of the observed reactions.


Table 1

Evaluation scale for skin reactions

SEVERITY OF OBSERVED REACTIONS	SCORE
None	0
Light, hardly noticeable	1
Moderate	2
Severe	3

6.2. Subjective Evaluation

At the end of the study the 100 subjects who took part to the study answered to a question relative to a subjective evaluation of the product tolerability.



7. DATA ANALYSIS AND PRODUCT CLASSIFICATION

Scores assigned for erythema, desquamation, oedema and vesicle were registered for each volunteer at each observational time (T15 and T30 days). They were cumulatively considered and averaged. This allowed to extrapolate the Mean Irritation Index (MII).

The product tolerability was classified on the basis of The Mean Irritation Index according to range of values reported in Table 2.

Table 2


MII	CLASSES
≤ 0.4	Not irritant
$0.5 \leq \text{MII} \leq 1.9$	Lightly irritant
$2.0 \leq \text{MII} \leq 4.9$	Moderately irritant
$5.0 \leq \text{MII} \leq 8.0$	Strongly irritant

Note: results were interpreted according to ISO 10993-10 AMD 1:2004 (Biological evaluation of medical devices - Part 10: Tests for irritation and delayed-type hypersensitivity), which applies a 0.4 cut-off for positive outcomes. On this basis, the effect of modest reactivity, which is often observed due to the exaggerated exposure conditions of this test, do not influence the final interpretation.

8. RESULTS

8.1. Results of the clinical evaluation


EVALUATED PARAMETERS	MEAN SCORE after 15 days of product use	MEAN SCORE after 30 days of product use
ERYTHEMA	0	0
DESQUAMATION	0	0
OEDEMA	0	0
VESICLES	0	0
TOTAL	0	0
<u>MII</u>	0	0



8.2. Results of subjective evaluation

At the end of the study the 100 subjects who took part to the study answered to a question relative to a subjective evaluation of the product tolerability; here below is reported the question and the relative answers in form of graph.

- **After/during the product usage did you noticed any adverse effect caused by the product itself (irritation, itching, burning sensation, redness, etc...)?**



9. DISCUSSION AND CONCLUSIONS

The calculation of Mean Irritation Index, under the adopted experimental conditions, allowed to classify the test substance

TAM- 818 Serum

as **NOT IRRITANT and TOLERATE/COMPATIBLE with the skin**

Moreover the product use didn't significantly modified the initial conditions in the application skin area, concerning the onset of erythema, desquamation, oedema and vescicles.


These conclusions are confirmed from the results obtained from the subjective evaluation about dermal tolerability of the product expressed by each volunteer who took part to the study.

10. ARCHIVING

The study protocol, the raw data and the final report will be kept in the archives of Abich Clinical and Cosmetological Trials Center, in Via Buozzi, 4, 20090-Vimodrone (MI), both in electronic format and in reduced paper format for a period of 10 years from the issue of the final report.

The control sample of the test substance and eventual specific reference material will be kept for 1 month, unless a specific request is provided by the customer.

The Customer, upon drafting a suitable contract, may request either the extension of the conservation of all or part of the materials for a further period or their restitution.



11. REFERENCES

Magnusson B. et al. : "Routine patch testing". II Acta Dermatovenereol. 46,153, (1966).

Fregert S. et al. : "Epidemiology of contact dermatitis". Trans. ST. John's Hosp. Derm. Soc. 55,17, (1969).

Pirila V. : "Chamber test versus patch test for epicutaneous testing". Contact Dermatitis I, 48, (1975).

"Guidelines for the Assessment of Skin Tolerance of Potentially Irritant Cosmetic Ingredients" Edition of 1997

Declaration WORLD MEDICAL ASSOCIATION DECLARATION OF HELSINKI

Ethical Principles for Medical Research Involving Human Subjects

Adopted by the 18th WMA General Assembly, Helsinki, Finland, June 1964, and amended by the:

29th WMA General Assembly, Tokyo, Japan, October 1975

35th WMA General Assembly, Venice, Italy, October 1983

41st WMA General Assembly, Hong Kong, September 1989

48th WMA General Assembly, Somerset West, Republic of South Africa, October 1996

52nd WMA General Assembly, Edinburgh, Scotland, October 2000

53rd WMA General Assembly, Washington 2002 (Note of Clarification on paragraph 29 added)

55th WMA General Assembly, Tokyo 2004 (Note of Clarification on Paragraph 30 added)

59th WMA General Assembly, Seoul, October 2008

64th WMA General Assembly, Fortaleza, Brazil, October 2013

Brasch J., Geier H. Henseler T.: "Evaluation of patch test results by use of the reaction index. An analysis of data recorded by the information network of departments of dermatology". Contact Dermatitis, 33:385-380, (1995).

Consensus documents Number 4.

OECD SERIES ON PRINCIPALES OF GLP AND COMPLIANCE MONITORING

"Quality assurance and GLP" 26 Oct. 1999.

Consensus documents Number 5.

OECD SERIES ON PRINCIPALES OF GLP AND COMPLIANCE MONITORING

"Compliance of laboratory suppliers with GLP principles" 28 Sept. 2000.

Consensus documents Number 7.


OECD SERIES ON PRINCIPALES OF GLP AND COMPLIANCE MONITORING

"The application of to GLP principles to short term studies" 15 Sept. 1999.

Consensus documents Number 8.

OECD SERIES ON PRINCIPALES OF GLP AND COMPLIANCE MONITORING

"The role and responsibility of the Study Director in the GLP studies" 15 Sept. 1999.




12. ANNEXES

ANNEX 1


Inci list TAM- 818 Serum

Aqua, Jojoba Esters, Macadamia Integrifolia (Seed) Oil, Ethyl Macadamiate, Isoamyl Laurate, Lecithin, Polyglyceryl-10 Stearate, Helianthus Annuus (Sunflower seed) Oil, phospholipids, Sodium Acrylates Copolymer, Glyceryl Caprylate, Isopropyl myristate, Glycerin, Hydrogenated Polyisobutene, Polyglyceryl-6 Caprylate, Caprylhydroxamic acid, Propanediol, phytosphingosine, Sodium Phytate, TAM-818.




ANNEX 2


Control 1: Clinical evaluation of the treated area at T0 (basal values from 0 to 3)						
N° Vol.	Vol. Code	ERYTHEMA	DESQUAMATION	OEDEMA	VESCICLES	TOTAL
1	adci526	0	0	0	0	0
2	ancon12	0	0	0	0	0
3	aniz367	0	0	0	0	0
4	anla484	0	0	0	0	0
5	anla7	0	0	0	0	0
6	anpan13	0	0	0	0	0
7	anpe409	0	0	0	0	0
8	anpe440	0	0	0	0	0
9	ansa120	0	0	0	0	0
10	arsu460	0	0	0	0	0
11	bami523	0	0	0	0	0
12	brti103	0	0	0	0	0
13	cabo441	0	0	0	0	0
14	caca55	0	0	0	0	0
15	cama505	0	0	0	0	0
16	caro420	0	0	0	0	0
17	chce155	0	0	0	0	0
18	clbe483	0	0	0	0	0
19	criquat14	0	0	0	0	0
20	crta129	0	0	0	0	0
21	dabe206	0	0	0	0	0
22	dalo334	0	0	0	0	0
23	debo349	0	0	0	0	0
24	dima287	0	0	0	0	0
25	dipi365	0	0	0	0	0
26	doca447	0	0	0	0	0
27	dogi445	0	0	0	0	0
28	elca122	0	0	0	0	0
29	eliv342	0	0	0	0	0
30	eman525	0	0	0	0	0
31	esa8	0	0	0	0	0
32	fead421	0	0	0	0	0
33	fipl275	0	0	0	0	0
34	fipa355	0	0	0	0	0
35	frga90	0	0	0	0	0




36	frma177	0	0	0	0	0
37	gaam497	0	0	0	0	0
38	gabr259	0	0	0	0	0
39	Gati439	0	0	0	0	0
40	gica434	0	0	0	0	0
41	giga455	0	0	0	0	0
42	gigr222	0	0	0	0	0
43	gima500	0	0	0	0	0
44	gipi527	0	0	0	0	0
45	giufi20	0	0	0	0	0
46	kadi493	0	0	0	0	0
47	lalom4	0	0	0	0	0
48	lata251	0	0	0	0	0
49	lili254	0	0	0	0	0
50	liva137	0	0	0	0	0
51	lode61	0	0	0	0	0
52	loma2	0	0	0	0	0
53	lopo479	0	0	0	0	0
54	lotu144	0	0	0	0	0
55	lual476	0	0	0	0	0
56	lubel22	0	0	0	0	0
57	lude228	0	0	0	0	0
58	ludi5	0	0	0	0	0
59	lufiu18	0	0	0	0	0
60	luge86	0	0	0	0	0
61	lupr276	0	0	0	0	0
62	luri265	0	0	0	0	0
63	lute520	0	0	0	0	0
64	lutuc9	0	0	0	0	0
65	maal258	0	0	0	0	0
66	maap492	0	0	0	0	0
67	maca268	0	0	0	0	0
68	maca64	0	0	0	0	0
69	macat1	0	0	0	0	0
70	made135	0	0	0	0	0
71	malu257	0	0	0	0	0
72	mama444	0	0	0	0	0
73	mela164	0	0	0	0	0
74	migi167	0	0	0	0	0
75	miro432	0	0	0	0	0




76	mobe354	0	0	0	0	0
77	more267	0	0	0	0	0
78	nagr443	0	0	0	0	0
79	nama501	0	0	0	0	0
80	paba487	0	0	0	0	0
81	pamu418	0	0	0	0	0
82	pavi307	0	0	0	0	0
83	pivi463	0	0	0	0	0
84	rast348	0	0	0	0	0
85	ricl480	0	0	0	0	0
86	riia62	0	0	0	0	0
87	roca128	0	0	0	0	0
88	roia359	0	0	0	0	0
89	romi370	0	0	0	0	0
90	rote181	0	0	0	0	0
91	rova262	0	0	0	0	0
92	saca272	0	0	0	0	0
93	saca38	0	0	0	0	0
94	sagi270	0	0	0	0	0
95	sapo213	0	0	0	0	0
96	sigi469	0	0	0	0	0
97	tecri3	0	0	0	0	0
98	tiba281	0	0	0	0	0
99	tira309	0	0	0	0	0
100	vidi524	0	0	0	0	0
MEAN		0	0	0	0	0




Control 2: Clinical evaluation of the treated area at T15 (values from 0 to 3)						
N° Vol.	Vol. Code	ERYTHEMA	DESQUAMATION	OEDEMA	VESCICLES	TOTAL
1	adci526	0	0	0	0	0
2	ancon12	0	0	0	0	0
3	aniz367	0	0	0	0	0
4	anla484	0	0	0	0	0
5	anla7	0	0	0	0	0
6	anpan13	0	0	0	0	0
7	anpe409	0	0	0	0	0
8	anpe440	0	0	0	0	0
9	ansa120	0	0	0	0	0
10	arsu460	0	0	0	0	0
11	bami523	0	0	0	0	0
12	brti103	0	0	0	0	0
13	cabo441	0	0	0	0	0
14	caca55	0	0	0	0	0
15	cama505	0	0	0	0	0
16	caro420	0	0	0	0	0
17	chce155	0	0	0	0	0
18	clbe483	0	0	0	0	0
19	criquat14	0	0	0	0	0
20	crt129	0	0	0	0	0
21	dabe206	0	0	0	0	0
22	dalo334	0	0	0	0	0
23	debo349	0	0	0	0	0
24	dima287	0	0	0	0	0
25	dipi365	0	0	0	0	0
26	doca447	0	0	0	0	0
27	dogi445	0	0	0	0	0
28	elca122	0	0	0	0	0
29	eliv342	0	0	0	0	0
30	eman525	0	0	0	0	0
31	esa8	0	0	0	0	0
32	fead421	0	0	0	0	0
33	fipl275	0	0	0	0	0
34	fipa355	0	0	0	0	0
35	frga90	0	0	0	0	0
36	frma177	0	0	0	0	0
37	gaam497	0	0	0	0	0




38	gabr259	0	0	0	0	0
39	Gati439	0	0	0	0	0
40	gica434	0	0	0	0	0
41	giga455	0	0	0	0	0
42	gigr222	0	0	0	0	0
43	gima500	0	0	0	0	0
44	gipi527	0	0	0	0	0
45	giufi20	0	0	0	0	0
46	kadi493	0	0	0	0	0
47	lalom4	0	0	0	0	0
48	lata251	0	0	0	0	0
49	lili254	0	0	0	0	0
50	liva137	0	0	0	0	0
51	lode61	0	0	0	0	0
52	loma2	0	0	0	0	0
53	lopo479	0	0	0	0	0
54	lotu144	0	0	0	0	0
55	lual476	0	0	0	0	0
56	lubel22	0	0	0	0	0
57	lude228	0	0	0	0	0
58	ludi5	0	0	0	0	0
59	lufiu18	0	0	0	0	0
60	luge86	0	0	0	0	0
61	lupr276	0	0	0	0	0
62	luri265	0	0	0	0	0
63	lute520	0	0	0	0	0
64	lutuc9	0	0	0	0	0
65	maal258	0	0	0	0	0
66	maap492	0	0	0	0	0
67	maca268	0	0	0	0	0
68	maca64	0	0	0	0	0
69	macat1	0	0	0	0	0
70	made135	0	0	0	0	0
71	malu257	0	0	0	0	0
72	mama444	0	0	0	0	0
73	mela164	0	0	0	0	0
74	migi167	0	0	0	0	0
75	miro432	0	0	0	0	0
76	mobe354	0	0	0	0	0
77	more267	0	0	0	0	0




78	nagr443	0	0	0	0	0
79	nama501	0	0	0	0	0
80	paba487	0	0	0	0	0
81	pamu418	0	0	0	0	0
82	pavi307	0	0	0	0	0
83	pivi463	0	0	0	0	0
84	rast348	0	0	0	0	0
85	ricl480	0	0	0	0	0
86	riia62	0	0	0	0	0
87	roca128	0	0	0	0	0
88	roia359	0	0	0	0	0
89	romi370	0	0	0	0	0
90	rote181	0	0	0	0	0
91	rova262	0	0	0	0	0
92	saca272	0	0	0	0	0
93	saca38	0	0	0	0	0
94	sagi270	0	0	0	0	0
95	sapo213	0	0	0	0	0
96	sigi469	0	0	0	0	0
97	tecri3	0	0	0	0	0
98	tiba281	0	0	0	0	0
99	tira309	0	0	0	0	0
100	vidi524	0	0	0	0	0
MEAN		0	0	0	0	0



Control 3: Clinical evaluation of the treated area at T30 (values from 0 to 3)						
N° Vol.	Vol. Code	ERYTHEMA	DESQUAMATION	OEDEMA	VESCICLES	TOTAL
1	adci526	0	0	0	0	0
2	ancon12	0	0	0	0	0
3	aniz367	0	0	0	0	0
4	anla484	0	0	0	0	0
5	anla7	0	0	0	0	0
6	anpan13	0	0	0	0	0
7	anpe409	0	0	0	0	0
8	anpe440	0	0	0	0	0
9	ansa120	0	0	0	0	0
10	arsu460	0	0	0	0	0
11	bami523	0	0	0	0	0
12	brti103	0	0	0	0	0
13	cabo441	0	0	0	0	0
14	caca55	0	0	0	0	0
15	cama505	0	0	0	0	0
16	caro420	0	0	0	0	0
17	chce155	0	0	0	0	0
18	clbe483	0	0	0	0	0
19	criquat14	0	0	0	0	0
20	crt129	0	0	0	0	0
21	dabe206	0	0	0	0	0
22	dalo334	0	0	0	0	0
23	debo349	0	0	0	0	0
24	dima287	0	0	0	0	0
25	dipi365	0	0	0	0	0
26	doca447	0	0	0	0	0
27	dogi445	0	0	0	0	0
28	elca122	0	0	0	0	0
29	eliv342	0	0	0	0	0
30	eman525	0	0	0	0	0
31	esa8	0	0	0	0	0
32	fead421	0	0	0	0	0
33	fipl275	0	0	0	0	0
34	fipa355	0	0	0	0	0
35	frga90	0	0	0	0	0
36	frma177	0	0	0	0	0
37	gaam497	0	0	0	0	0



38	gabr259	0	0	0	0	0
39	Gati439	0	0	0	0	0
40	gica434	0	0	0	0	0
41	giga455	0	0	0	0	0
42	gigr222	0	0	0	0	0
43	gima500	0	0	0	0	0
44	gipi527	0	0	0	0	0
45	giufi20	0	0	0	0	0
46	kadi493	0	0	0	0	0
47	lalom4	0	0	0	0	0
48	lata251	0	0	0	0	0
49	lili254	0	0	0	0	0
50	liva137	0	0	0	0	0
51	lode61	0	0	0	0	0
52	loma2	0	0	0	0	0
53	lopo479	0	0	0	0	0
54	lotu144	0	0	0	0	0
55	lual476	0	0	0	0	0
56	lubel22	0	0	0	0	0
57	lude228	0	0	0	0	0
58	ludi5	0	0	0	0	0
59	lufiu18	0	0	0	0	0
60	luge86	0	0	0	0	0
61	lupr276	0	0	0	0	0
62	luri265	0	0	0	0	0
63	lute520	0	0	0	0	0
64	lutuc9	0	0	0	0	0
65	maal258	0	0	0	0	0
66	maap492	0	0	0	0	0
67	maca268	0	0	0	0	0
68	maca64	0	0	0	0	0
69	macat1	0	0	0	0	0
70	made135	0	0	0	0	0
71	malu257	0	0	0	0	0
72	mama444	0	0	0	0	0
73	mela164	0	0	0	0	0
74	migi167	0	0	0	0	0
75	miro432	0	0	0	0	0
76	mobe354	0	0	0	0	0



77	more267	0	0	0	0	0
78	nagr443	0	0	0	0	0
79	nama501	0	0	0	0	0
80	paba487	0	0	0	0	0
81	pamu418	0	0	0	0	0
82	pavi307	0	0	0	0	0
83	pivi463	0	0	0	0	0
84	rast348	0	0	0	0	0
85	ricl480	0	0	0	0	0
86	riia62	0	0	0	0	0
87	roca128	0	0	0	0	0
88	roia359	0	0	0	0	0
89	romi370	0	0	0	0	0
90	rote181	0	0	0	0	0
91	rova262	0	0	0	0	0
92	saca272	0	0	0	0	0
93	saca38	0	0	0	0	0
94	sagi270	0	0	0	0	0
95	sapo213	0	0	0	0	0
96	sigi469	0	0	0	0	0
97	tecri3	0	0	0	0	0
98	tiba281	0	0	0	0	0
99	tira309	0	0	0	0	0
100	vidi524	0	0	0	0	0
MEAN		0	0	0	0	0